August 1st 2025
Paris, August 1, 2025 – 2:00 pm CEST
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today provides an update on the ongoing receivership procedure and announces the resumption of CARMAT shares trading, starting on August 4, 2025, at stock market opening.
Update on the ongoing receivership procedure
On July 3, 2025, CARMAT had announced the initiation of a call for public tenders (buyers or investors) as part of the receivership opened on July 1, 2025. The deadline for submitting offers was July 31, 2025.
At that date, one takeover bid within the context of a sales plan (the “Bid”) has been received by the judiciary administrator. The Bid, which is still subject to adjustments, will be assessed by the Versailles Economic Court (the “Court”) at a hearing scheduled on August 19, 2025.
The Company draws attention to the fact that there is no guarantee at this stage that this Bid will be successful. As a consequence, CARMAT remains subject to a risk of liquidation, including in the short term. The Company also reminds that even if the Bid is validated by the Court, the Company’s shareholders and creditors may incur a significant loss of up to the total value of their investment or receivables.
Resumption of CARMAT shares trading (ISIN code: FR0010907956, Ticker: ALCAR)
CARMAT is going to ask Euronext to resume the trading of its shares starting on August 4, 2025, at stock market opening.
Press releases will be issued regularly as the Company’s situation evolves and the proceedings progress.
In any case, CARMAT endeavors to provide continuous support to patients who currently benefit from its Aeson® artificial heart.
[1] In French : « Offre de reprise en plan de cession ».